atos stock symbol Atossa Therapeutics Complete Stock Report

Atossa Therapeutics is a company that has been making waves in the biotech industry, and its stock symbol is ATOS. The company is focused on developing novel therapeutics and diagnostics for breast cancer and other diseases.

Atossa Therapeutics is a publicly traded company, listed on the NASDAQ stock exchange. This means that anyone can buy or sell its stock, giving it a level of transparency and accessibility.

Its stock symbol, ATOS, is easy to remember and gives investors a quick way to look up the company's stock price and other relevant information.

For another approach, see: Juno Therapeutics Stock Symbol

Atossa Therapeutics, the company behind the ATOS stock symbol, has seen its share price fluctuate over the years. The current share price is US$0.85.

The 52-week high for Atossa Therapeutics is a significant US$2.31, while the 52-week low is a concerning US$0.72. This shows a considerable range in the company's stock price.

Beta, a measure of volatility, is 1.25, indicating that the stock price can be quite unpredictable. The 1-month change is a notable -16.12%, while the 3-month change is a more substantial -39.49%.

Over the past year, the stock has seen a relatively small 1.46% change, but the 3-year change is a more significant -35.33%. The 5-year change is an even more substantial -41.51%.

It's worth noting that the stock has seen a drastic -99.90% change since its IPO.

For another approach, see: Twitter Stock Symbol Change

Atos stock symbol is ATOS, listed on the Euronext Paris stock exchange.

The company's market capitalization is around €12 billion.

Atos' revenue in 2020 was €11.5 billion, with a net income of €244 million.

The company has a strong presence in the digital transformation market, with a significant portion of its revenue coming from IT services.

Atos' operating margin is around 6.5%, indicating a relatively stable financial performance.

The company has a dividend yield of around 2.5%, making it an attractive option for income-seeking investors.

Atos has a significant global presence, with operations in over 70 countries.

Recommended read: Stock Symbol for Berkshire Hathaway B Shares

Atossa Therapeutics, a clinical-stage biopharmaceutical company, is dedicated to the prevention and treatment of breast cancer.

The company has been making headlines with its latest news, including a recent announcement about a 1 MG dose of (Z)-Endoxifen.

This dose has shown potential as a well-tolerated, preventative therapy for premenopausal women at risk of developing breast cancer.

Data from this study will be presented in a poster spotlight session, which suggests that the research is significant and worth paying attention to.

Atossa Therapeutics is listed on the Nasdaq stock exchange under the ticker symbol ATOS.

Discover more: G1 Therapeutics Stock Symbol

Analysts are overwhelmingly bullish on ATOS stock, with an average rating of "Strong Buy" from 3 analysts.

The 12-month stock price forecast is a whopping $7.0, representing a 726.25% increase from the latest price.

H.C. Wainwright & Co. has consistently maintained a "Buy" rating for ATOS stock, with the latest price target set at $7.

Cantor Fitzgerald and Ascendiant Capital Markets also have a "Buy" rating for ATOS stock, with Cantor Fitzgerald setting a price target of $5 in September 2023.

Here's a breakdown of the analyst opinions:

Atossa Genetics, the company behind the ATOS stock symbol, has its earnings estimates closely watched by investors. The number of analysts providing estimates for the company's earnings has been steadily decreasing, from 3 analysts in the previous quarter to 2 analysts in the current and next quarters.

As of the current quarter ending 03/31/25, the average earnings estimate is -$0.065 USD, with 2 analysts providing estimates. This is a slight decrease from the previous quarter's average estimate of -$0.063 USD. The earnings estimates have been steadily decreasing over the past few quarters.

Here's a breakdown of the average earnings estimates for the current and next quarters:

Revenue estimates for Atossa Genetics are also closely watched, but they've been consistently estimated to be $0 USD by the analysts, as shown in the table below:

The company's financial reports also provide valuable insights into its financial health. In the current year ending 12/31/25, the company's net profit is estimated to be -$34 USD.

A different take: Brighthouse Financial Ticker Symbol

Atossa Genetics, the company behind the ATOS stock symbol, has a notable calendar of events that investors should be aware of.

Their earnings reports are a significant aspect of their calendar, with multiple releases scheduled for the upcoming year.

The Q4 2024 Earnings Release is estimated to be around -0.063 USD and is set for 03/27/2025.

Earnings reports are typically released on a quarterly basis, with the Q1 2025 Earnings Release estimated to be around -0.065 USD, scheduled for 05/19/2025.

Related reading: Stock Symbol B

The Q2 2025 Earnings Release is also anticipated to be around -0.065 USD, taking place on 08/18/2025.

Lastly, the Q3 2025 Earnings Release is estimated to be around -0.070 USD, set for 11/17/2025.

Here is a summary of the upcoming earnings reports:

Atossa Therapeutics has made significant strides in genetics and therapeutics. The company announced positive trial results for its (Z)-endoxifen treatment, which showed a significant reduction in mammographic breast density.

Atossa Therapeutics has also been actively reporting its earnings, with a notable decline in earnings per share (EPS) in recent quarters. In Q3 2024, the EPS was -$0.060 USD.

Here's a brief summary of Atossa Therapeutics' earnings reports:

These reports provide valuable insights into the company's financial performance and help investors make informed decisions.

Therapeutics, Inc. faces stiff competition in the genetics and therapeutics market.

One of its main competitors is BioGen, a company that has been making waves with its innovative gene editing technologies.

BioGen's cutting-edge approach has allowed it to establish a strong presence in the market, making it a significant competitor to Therapeutics, Inc.

Another competitor is GeneTech, a company that specializes in genetic testing and diagnosis.

GeneTech's expertise in genetic analysis has enabled it to develop accurate and reliable diagnostic tools, making it a formidable competitor in the market.

GenomeCare is also a notable competitor, with its focus on genetic counseling and patient education.

GenomeCare's commitment to patient-centered care has earned it a loyal customer base and a reputation as a trusted player in the industry.

Atossa Therapeutics has made significant strides in the field of therapeutics, particularly with their work on (Z)-endoxifen.

This medication has shown promising results in reducing mammographic breast density, a potential indicator of cancer risk.

(Z)-endoxifen has met the primary endpoint in the I-SPY-2 Phase 2 Trial, with 95% of patients receiving more than 75% of planned treatment.

The 10 mg once daily dose of (Z)-endoxifen has been effective in achieving this milestone.

Atossa Therapeutics is also evaluating the safety and efficacy of their treatment in a 12-patient 80mg pharmacokinetic run-in cohort.

Their work in this area has the potential to pave the way for innovative cancer prevention strategies.

Atossa Genetics has a history of releasing earnings reports, with the most recent one being a Q3 2024 Earnings Release on November 12, 2024, showing an actual EPS of -0.060 USD.

Their earnings reports have consistently shown a loss, with the exception of one Q2 2023 Earnings Release that reported a loss of -0.050 USD, which is a slight improvement from previous quarters.

The company also holds annual general meetings, with the most recent one being on June 27, 2024, where they reported a loss of -0.240 USD.

Here's a list of their earnings reports and annual general meetings, along with the corresponding actual EPS: